PCM
BNTX icon

Pentwater Capital Management’s BioNTech BNTX Stock Holding History

Pentwater Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,000
Closed -$546K – 315
2021
Q1 		$546K Hold
5,000
– – 0.01% 271
2020
Q4 		$408K Hold
5,000
– – ﹤0.01% 204
2020
Q3 		$346K Buy
+5,000
New +$359K ﹤0.01% 198

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Pentwater Capital Management's BNTX Position: Q2 2021 in Review

Pentwater Capital Management sold out of BioNTech (BNTX) in Q2 2021, closing a stake of 5,000 shares — an estimated $546K sold.

Pentwater Capital Management first reported a position in BNTX in Q3 2020 and held it in 3 quarters. The position peaked at $546K in Q1 2021. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2021.

  • Pentwater Capital Management reported no remaining BioNTech position as of Q2 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 5,000 BioNTech shares in Q2 2021, an estimated $546K.
  • Pentwater Capital Management first reported a position in BioNTech in Q3 2020 and held it in 3 quarters.
  • Pentwater Capital Management's BioNTech position peaked at $546K in Q1 2021.
  • 283 funds tracked by Wall St. Rank held BioNTech as of Q2 2021.

Based on Pentwater Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.